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Abstract
The benefits of local production of pharmaceuticals in Africa for local access to medicines and to ef-
fective treatment remain contested. There is scepticism among health systems experts internation-
ally that production of pharmaceuticals in sub-Saharan Africa (SSA) can provide competitive prices,
quality and reliability of supply. Meanwhile low-income African populations continue to suffer poor
access to a broad range of medicines, despite major international funding efforts. A current wave of
pharmaceutical industry investment in SSA is associated with active African government promotion
of pharmaceuticals as a key sector in industrialization strategies. We present evidence from inter-
views in 2013–15 and 2017 in East Africa that health system actors perceive these investments in local
production as an opportunity to improve access to medicines and supplies. We then identify key poli-
cies that can ensure that local health systems benefit from the investments. We argue for a ‘local
health’ policy perspective, framed by concepts of proximity and positionality, which works with local
priorities and distinct policy time scales and identifies scope for incentive alignment to generate mu-
tually beneficial health–industry linkages and strengthening of both sectors. We argue that this local
health perspective represents a distinctive shift in policy framing: it is not necessarily in conflict with
‘global health’ frameworks but poses a challenge to some of its underlying assumptions.
Keywords: Local production of medicines, Africa, access to medicines, health system, health-industry linkages, local health,
global health
Key Messages
• The health system benefits of local production of pharmaceuticals in SSA are contested, while access to medicines re-
mains generally poor.
• A current wave of pharmaceutical industry investment offers an opportunity to link industrialization to improved access
to medicines.
• A ‘local health’ policy perspective can identify policies for health–industry linkages that benefit both health systems and
industrial development.
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Introduction
In international research and policy debates, health system
strengthening and industrial development have been generally ad-
dressed within two separate silos (Mackintosh et al. 2007, 2016).
When health–industry linkage in sub-Saharan Africa (SSA) has been
raised, each silo has viewed the proposition with scepticism.
International health experts have doubted Africa-based manufac-
turers’ capabilities to supply competitively priced, good quality
medicines on a timely basis (Kaplan and Laing 2005; Seiter 2005;
Kaplan et al. 2011; Wilson et al. 2012), fearing therefore a negative
impact on medicines access. Industrialization experts meanwhile
have focused on promotion of lower technology export sectors and
primary product processing in Africa, by implication regarding
pharmaceuticals as too complex with too high a learning curve and
regulatory/governance requirements (Dinh et al. 2012; Lin 2013).
Public health research meanwhile has largely ignored industrializa-
tion as a social determinant of health (CSDH 2008; Battams and
Matlin 2013), while research on health systems strengthening has
lumped industry into a general category of other relevant input sec-
tors (Bigdeli et al. 2014).
However policy makers, industrialists and researchers in Africa
are increasingly exploring and promoting synergies between local in-
dustrial production of pharmaceuticals and medical supplies and im-
provement in coverage and quality of health care, especially for low-
income populations (Government of Uganda 2002; Republic of
Ghana 2004; African Union 2007, 2012; Berger et al. 2010;
Government of Kenya 2010; EAC 2011; FDRE 2015; Gebre-
Mariam et al. 2016; URT 2016). International organizations have
responded: the World Health Organization (WHO) strategic frame-
work for medicines and health products (WHO 2017a: 8, 12) recog-
nizes the relevance of local manufacturing of quality medicines and
health products for access, a view reflecting collaborative UN re-
search and policy (UNCTAD 2011; WHO 2011a; Sidibe´ et al.
2014). Linkages between health policy and industrial change in low
and middle income country (LMIC) contexts more broadly are in-
creasingly researched (Srinivas 2012; Shadlen and Massard da
Fonseca 2013).
Meanwhile, low-income populations in SSA continue to suffer
severely inadequate and exclusionary health care undermined by
poor access to medicines and supplies (Wagner et al. 2011; WHO
2011b; Bigdeli et al. 2014; Wirtz et al. 2017). Median availability of
essential medicines 2007–14 was only 60% overall, and 56% in the
public sector of low/lower-middle-income countries (WHO 2017b:
11), and has changed little in SSA countries (UN 2015: 55–6), des-
pite major funding efforts for HIV and TB medication (IHME
2017). Better access and more appropriate use are required for all
the aspects of health system strengthening in the Universal Health
Coverage (UHC) 2030 Joint Vision (WHO/World Bank 2017): for
reducing severe inequity, and improving quality, responsiveness, ef-
ficiency and resilience.
This article draws on recent fieldwork to address the implica-
tions for global health of the shift in African perspectives on health–
industry linkages, a shift embedded in a wider policy narrative on
building resilient, inclusive and sustainable economic systems
(African Union 2014a). We first outline a ‘local health’ framework
emerging from interviews and data collection, mainly in Tanzania
and Kenya. We then trace how this perspective embeds health sys-
tem strengthening within local industrial–health system linkages and
wider economic, technological and industrial development. Finally,
we discuss the implications for global health perspectives.
‘Local health’: reframing health system
strengthening
A concept of ‘local health’, as it emerges in our interviews and cur-
rent African policy debate, is rooted in a dialogue between proximity
and positionality. ‘Proximity’ refers to cumulative local interactions
and mutual influences arising from co-location (Boschma 2005).
‘Positionality’ (Rowson et al. 2012) refers to the influence of location
of agency on the framing of issues and priorities, with attendant
claims to power and legitimacy in policy making.
Proximity can usefully be analysed on three dimensions: geo-
graphical proximity, relational proximity and the values assigned to
proximity (Eriksen 2013). In health research, geographical proxim-
ity is measured as a determinant or index of accessibility of services;
in industrial development, as an explanatory factor of industrial
clustering of related industries. In health–industry linkages, geo-
graphical proximity potentially generates more rapid supply re-
sponse. Relational proximity echoes the health literature‘s
recognition of local culture as an important determinant and con-
tributor to health services’ response to population needs (Hahn and
Inhorn 2009); in industry, it reflects what has been called industrial
‘atmosphere’, the cumulative benefits of local learning and spillovers
of tacit knowledge (Ravix 2014) and relationships with universities
and government. In health–industry linkages, it reflects the scope for
a more agile response to local needs within local economies. Finally,
the values given to proximity can be picked up in mutual under-
standing, legitimation and trust in known health care providers; in
collaboration between input and final product producers; and in
merited trust in locally produced health care products.
Positionality, defined by local power, agency and responsibility,
is reflected in locally distinctive priorities and in sharply differenti-
ated views—as compared to global health approaches—on risk, se-
curity and timescales for policy making. For example, local
interviews on health supplies emergency planning priorities focused
on day-to-day immediate emergency needs, while for pandemic pre-
paredness, a central concern was local scientific competence and
production capacity, recognizing a positionality-derived imperative
on governments to protect their own populations first.
These distinctive local concerns pull closer together policies for
industry, science and health around strengthening security of
pharmaceutical supplies for local health care. They interconnect risk
management with local health security, safety and responsibility. As
Giddens (1999: 7–9) argues, in contexts of uncertainty and innov-
ation, risk and responsibility are closely interrelated. For local policy
makers to assume greater responsibility for medium term risk man-
agement requires the building of greater technical and organiza-
tional capability in health- and industry-related skills. Increasingly
this imperative is framed in terms of ownership: ‘To be able to gen-
erate wealth and give its future generations a chance, Africa must
take ownership of its health’ (Lopes 2014). Positionality thus in-
vokes claims of legitimacy for policy and practice.
We trace in our findings the implications of this ‘local health’ per-
spective in local health policy, and the emerging interconnections with
industrial change. We document the locally perceived relevance of local
production for health, and explore the scope for incentive alignment
across sectors. The Findings subsections thus identify what potential
health benefits from industrial proximity are locally recognized; note
current policy scope for exploiting those synergies; and identify areas
where incentivizing industrial development in pharmaceuticals and
supplies can also incentivize responsiveness to health sector needs, and
conversely where reshaping procurement can open markets for local
firms, in an incentive–compatible spiral of improvement.
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Methods
Research on health system–industry relationships in 2012–151
included a first phase (2012–13) using a convergent parallel mixed
methods research design (Ozawa and Pongpirul 2014). A total of
160 qualitative interviews were conducted in 4 districts in Tanzania,
and 4 counties in Kenya, purposively selected to represent a wide
range of geographical area, incomes, infrastructure and health out-
comes, including 2 urban and 2 rural locations in each country.
Health facilities, pharmacies and drug shops (42 in Tanzania and 55
in Kenya) were purposively selected from public (32), faith-based/
NGO (17) and private (48) sectors. Semi-structured interviews cov-
ered procurement and supply processes and opinions on local vs im-
ported supplies, for medicines, medical supplies and equipment,
laboratory supplies and basics such as bed nets, sheets and cleaning
materials, using open-ended questions that invited free expression
and avoided leading interviewees. Quantitative data were also col-
lected on availability and source of a set of tracer essential medi-
cines, supplies and equipment on the day of the visit (listed in online
Supplementary Data— Supplementary data are available at Health
Policy and Planning online, and selected with advice from local
regulators and pharmaceutical experts).
In a second phase (2013–14), locally based manufacturers of
medicines, medical and other supplies, and of inputs such as packag-
ing (11 in Tanzania and 12 in Kenya) were interviewed, and 29
interviews conducted with government officials, wholesalers, pro-
curement agents, regulators, government officials and manufactur-
ing associations. Topics included business histories and strategies,
trading conditions, case studies of domestic market supply decisions,
and policy, regulatory and procurement frameworks and
experience.
In April–May 2017, 23 further interviews2 in Tanzania, Kenya
and Uganda on local pharmaceutical production and its implications
for health care included 6 manufacturers, 3 wholesalers (procure-
ment agencies and private distributors), 5 regulatory bodies and
government ministries; 7 clinicians, pharmacists and local pharma-
ceutical consultants and 2 East African Community (EAC) officials.
We also met a group of senior informants at The Global Fund in
Geneva. This article also draws on discussions with a broader net-
work of African experts in the context of meetings and consult-
ations, as well as secondary literature.
The quantitative data were analysed using Stata 11. The qualita-
tive data were coded and sorted into key themes using NVivo soft-
ware, then systematically analysed for distinct concepts and
arguments. This article presents mainly qualitative findings, triangu-
lated where appropriate with quantitative data. While the data set is
original and substantial, the quantitative findings of the 2012–13 re-
search are not statistically representative for either country.
Ethical clearance was obtained from the Open University
Human Research Ethics Committee in the UK, the Kenyatta
National Hospital Ethical Review Board in Kenya and the National
Institute for Medical Research Ethics Review Committee in
Tanzania. All participants consented to the research, having been
assured that participation was voluntary and that their anonymity
would be preserved in published research findings.
Findings
Is proximity in source of supplies a health policy
concern?
In Tanzania and Kenya, health sector informants consistently argued
that local manufacturing was relevant for availability of supplies,
and could improve it further, citing short supply chains, distribution
in rural areas, and scope for closer regulation and scrutiny than of
overseas suppliers. In both countries over half of medicines are ac-
cessed by private payment, while local manufactures’ prices fluctu-
ate with competitive market conditions and may be higher or lower
than Indian import prices (Mackintosh and Mujinja 2010; ACT
Watch et al. 2017; Ewen et al. 2017).
In both countries, some local firms had built brand recognition
and trust from clinicians and the public, e.g.:
Our patients . . . appreciate the products from Cosmos (Faith-
based health centre, Kenya).
Shelys has good-quality drugs which are readily available and the
price is affordable (Public health centre, Tanzania).
These firms are long established, with wide distribution networks,
and local production was seen as important for rural access.
Availability of basic medication is consistently worse in rural areas,
reflecting delivery difficulties and low demand due to very low in-
comes (Cohen et al. 2010; Mackintosh and Mujinja 2010; URT
2014). In Kenya, local products were widely preferred over Indian
imports where European imports were unaffordable, e.g.:
. . . the locally manufactured drugs are cheap . . .. mission hos-
pitals, clinics, district hospitals and local pharmacists in up-
country, they really support local manufacturers (Private hospital
Kenya).
Data on availability supported these assertions: in both countries
local products formed a higher share of tracer medicines available
on rural than on urban shelves in 2013 (Table 1).
In Tanzania, locally manufactured essential medicines have been
shown to reach rural locations more effectively than imported items
(Mujinja et al. 2014). Local manufacturers stated that they relied on
active rural distribution, using their own logistics, and one firm in
2017 was actively expanding its in-house distribution capability and
brand advertising to widen its market. Closing a rural/urban avail-
ability gap for subsidized imported antimalarial combination ther-
apy (ACTs) had required active interventions in distribution,
including rural subsidies in Kenya (Cohen et al. 2010; Morris et al.
2015; ACT Watch et al. 2017).
In both countries health sector informants in 2012–13 com-
plained about two aspects of local product quality: hardness—a ten-
dency for tablets to disintegrate before use—and poor packaging
quality. Local manufacturers also identified a problem with low
quality of local packaging suppliers.
Finally, when asked in 2017 about supplies for emergency pre-
paredness, all health sector respondents in Kenya and Tanzania
advocated local production of medicines to address day-to-day le-
thal emergencies, mentioning saline drips for cholera, oral
Table 1. Geographical source of tracer essential medicines avail-
able on day of visit, facilities and shops, all sectors, by rural/urban,
Tanzania and Kenya, 2013 (% of total by rural/urban location)
Manufacturing
location
Tanzania Kenya
Local External Local External
Rural 19.8 80.2 54.9 45.1
Urbana 13.0 87.0 35.5 64.5
Source: Calculated from fieldwork data 2013. Tanzania n¼ 646; Kenya
n¼ 1043.
aIn Tanzania, includes semi-urban areas on outskirts of cities and small
urban areas in rural districts.
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rehydration salts (ORS) for childhood diarrhoea, oxytocin for ma-
ternal haemorrhage, hydrocortisone, magnesium sulphate and
adrenaline for allergic reactions, asthma and pre-eclampsia.
Shortages of these items repeatedly cause emergency deaths. When
asked about pandemic preparedness, African stakeholders inter-
viewed in 2017 took a medium-term view, specifying building local
scientific, technological and production capabilities, including local
vaccine manufacturing, intellectual property (IP)-linked partnerships
with multinationals, and use of flexibilities under the Agreement on
Trade-Related Aspects of Intellectual Property Rights (TRIPS).
Should local health policy consider industrial benefits?
Some health sector interviewees in 2013 recognized broader social
and economic benefits from enhanced local production:
There are a lot of benefits, for example . . .. you’ll create employ-
ment by virtue of them manufacturing in this country (Private
pharmacy, Kenya).
Local pharmaceutical industries have been stimulated and so
have created employment (Drug shop, Tanzania).
Growing appreciation of these wider benefits was evident among
health sector interviewees in 2017 in Tanzania. Like many African
countries, Tanzania has shifted national policy emphasis towards
industrialization, including pharmaceutical manufacturing as a pri-
ority sector in its Five-Year Development Plan 2016–2021, aiming
explicitly to improve health care and enhance access to medicines
(URT 2016: 49). A Tanzanian Health Ministry official said in 2017:
‘we used to think very narrowly’, just health needs, but now they
also consider industrial benefits to Tanzania.
Health policy makers interviewed were thus aware of scope to
encourage, influence and take advantage of a current wave of
pharmaceutical investment, to respond to local health needs.
Across the East African region, the scope for health policy link-
ages with industry is expanding with new foreign and local invest-
ment. Tanzanian Health Ministry officials in 2017 were fielding
enquiries from potential overseas investors, including UAE, Egypt,
India, Pakistan and China. In Tanzania and Kenya, the most promin-
ent firm has recently been subject to overseas takeover: in Tanzania,
Aspen, a South African multinational now partly owned by GSK
completed purchase of Shelys in 2014; in Kenya in 2016, Strides, an
India-based multinational, took a controlling 51% interest in
Universal, the only Kenyan company with WHO product-
prequalification. In Uganda, Cipla, another India-based multina-
tional, has consolidated its investment in Cipla Quality Chemicals.
Further afield, rising pharmaceutical investment in Ethiopia has
included a Sino-Ethiopian joint venture between an Ethiopian dis-
tributor and China Associate Group, a company co-owned by a
large group of Chinese pharmaceutical companies, and also Middle
East investments (Gebre-Mariam et al. 2016). Local investors in
Tanzania have also been actively creating start-ups. Most firms in
Tanzania and Kenya remain locally owned, and when interviewed,
all were strongly focused on technological upgrading to meet Good
Manufacturing Practice (GMP) standards. Health sector buyers can
encourage and benefit from these rising standards, while also help-
ing to sustain domestic market competition. Manufacturers’ inter-
views, and contrasts between the manufacturing sector in Tanzania
and Kenya, identified some of the cumulative benefits that can be
generated from proximity within successful industrial clustering,
including: building local skilled labour pools; generating and sharing
technological knowledge and innovation skills; diversifying glo-
bal linkages; achieving local specialization; improving quality of in-
put suppliers; and generating scale economies and pressure
for regional market integration (see also Schmitz 1995; Nadvi and
Halder 2005).
Aligning incentives for local health and industrial
improvement
The key concerns about medicines expressed by health policy mak-
ers were quality, price and availability/reliable supply. The inter-
views identify areas where policies incentivizing industrial
development can also incentivize responsiveness to health sector
needs, and vice versa, extracting proximity benefits in the form of
synergy between sectors.
Relational procurement to improve local manufacturers’
responsiveness
Health sector actors can shape manufacturing suppliers through re-
lational procurement behaviour. The health sector provides a huge
market for industry, so health sector purchasing operates implicitly
as industrial policy (Chataway et al. 2016). The policy challenge is
to generate incentives for industrial behaviour that favours health
needs, reducing gaps and lead times through geographical and rela-
tional proximity while meeting quality hurdles.
Good practice exists in East Africa on working relationally with
local suppliers to build responsiveness. Public and non-profit pro-
curement agencies in Tanzania and Kenya already buy locally pro-
portionately more essential medicines than private wholesalers
(Table 2).
Not all local suppliers are responsive: in 2013, one non-profit
wholesaler in Tanzania had experienced some longer local lead
times than ordering from India. Experience shows these problems
can be overcome by procurement that works knowledgeably and
interactively with local manufacturers. The large FBO wholesaler in
Kenya, Mission for Essential Drugs & Supplies (MEDS) had bought
locally a high proportion of tracer medicines (Table 2), and all
Kenyan faith-based health facility interviews in 2013 attributed to
MEDS a high level of responsiveness, with rapid turnaround on
orders. MEDS attributed this performance to relational working.
Approved local suppliers were regularly inspected and monitored
for delivery times and product quality, using MEDS’ pre-qualified
laboratory, with sanctions for poor performance. MEDS used local
tenders, and provided tender information in advance so suppliers
could plan. Regular suppliers’ meetings provided feedback.
Other procurement bodies are now following this relational pro-
curement path. The Tanzanian government has revised its proced-
ures to permit the Tanzanian public procurement body, Medical
Supplies Department (MSD), to procure directly from manufac-
turers, rather than solely through private distributors. In 2017,
Table 2. Tanzania and Kenya 2013: Country of origin of tracer medi-
cines, % by wholesale sector
Country of origin Tanzania Kenya
Wholesale sector Wholesale sector
Public Private Public FBO/NGO Private
Tanzania 22 11
Kenya 10 20 54 76 32
India 49 47 30 8 31
Other 18 22 16 16 37
Total 100 100 100 100 100
Source: Fieldwork; columns may not add to 100 because of rounding.
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MSD described how it was building links with local firms. Close as-
sessment of firms’ capabilities had resulted in most local firms
receiving supply contracts in 2017; procurement adaptations had
included smaller contract size, and 2-year contract lengths to en-
courage firms to invest. Firms were required to offer short delivery
times, and MSD aimed to identify and share future market opportu-
nities with local firms.
In Kenya, health sector decentralization reforms devolved public
ordering of medicines and supplies to the counties, aiming to im-
prove responsiveness to local needs. The Kenya Medical Supplies
Authority (KEMSA) remains the primary public sector procurement
agent, and may establish county branches (Republic of Kenya 2015:
247–248). Organization reform in KEMSA has also included frame-
work contracts with local manufacturers, speeding up ordering
under pre-negotiated terms with more active contract management
(Yadav 2014).
The Global Fund procurement system,3 furthermore, now aims
to find and work actively with potential suppliers in Africa, reward-
ing cost and responsiveness advantages arising from geographical
proximity. The Fund engages with suppliers to identify areas for
bringing in production efficiencies and reducing costs, and supports
firms with market data.
Procurement agencies can also help to direct investment to priority
local needs. In Tanzania, MSD is encouraging existing firms to ex-
pand their product range: in the words of one government official,
fewer cough mixtures and more items of ‘real importance’. MSD is
also helping to identify opportunities for new investors, and to sup-
port new start-ups with small orders. Stated national priorities
included more producers of basic antibiotics such as amoxicillin, and
beginning local production of laboratory reagents—in constant short-
age. The local start-ups in Tanzania in 2017 included production
facilities for medical supplies such as bandages, dressings and gauze,
often in severely short supply, using locally produced inputs such as
cotton. Currently active investments and developed proposals in the
East African region also include more high-quality regional sources of
ACTs and of antiretroviral medication (ARVs) for HIV; also local
production of key medication for non-communicable diseases
(NCDs), including hypertension and diabetes, and more regional sup-
pliers of intravenous drips and parenteral preparations. Procurement
that exploits relational proximity can thus provide a market access in-
centive for competent firms to respond to health sector needs.
Incentivizing production of both basic and higher technology
products
The health sector needs affordable, good quality, secure supplies of
basic items, such as basic antibiotics, pain killers and ORS, and also
competent suppliers of more complex items. Incentivizing both out-
comes require well-designed pricing and competition policies.
Recent regional experience illustrates some of the conflicts and
routes to their resolution.
East Africa-based manufacturers face sharp price competition in
their domestic private markets and in bidding for tenders, since im-
ports benefit from the EAC’s zero common external tariff for essen-
tial health supplies, while some imported inputs face duties and
taxes. Africa-based manufacturers also suffer inherent cost disad-
vantages, notably inadequate and costly national infrastructure such
as power, water and transport, forcing complementary investments,
e.g. in back-up generation, and also market size constraints.
Economies of scale are not large in basic formulations (tablets and
capsules), but Africa-based manufacturers must import active
pharmaceutical ingredients (APIs) in smaller quantities, generally at
higher prices than competing Indian and Chinese firms. Local manu-
facturers can frequently meet competition by accepting lower mar-
gins than those earned on imports (Chaudhuri and West 2014).
However, import price competition appears to have intensified, not-
ably in basic antibiotics: Tanzanian interviewees in 2014 reported
amoxicillin imports priced below API import cost. Local supplies of
low margin basic essentials had dropped sharply in Tanzania,
including amoxicillin (Table 3), as local firms’ business strategies re-
focused on higher margin products.
Well-designed industrial protection can support prices and sus-
tain production of essential basics, contributing to firms’ bottom
line and cash flow, and also incentivize upgrading and quality im-
provement. It must be associated with active promotion of domestic
industrial competition to prevent an upward price spiral. What is
sometimes called the ‘Ghana model’ blocks imports of basic items
that can be produced locally: the Ghanaian list has recently ex-
panded to 49 medicines.4 It includes antibiotics, analgesics, ORS
and multivitamins, and the Food and Drugs Authority (FDA) of
Ghana will not accept new registrations of these medicines. East
African government procurement offers local firms a percentage
price uplift in public procurement: 15% in Tanzania and Uganda,
varying from 10% downwards according to local ownership in
Kenya, though in Kenya and Uganda manufacturing interviewees
said it was not consistently applied. Other incentives that increase
protection without challenging the EAC’s common tariff rules in-
clude a 2% import verification fee in Uganda, which may be raised
to 12%. Tanzania has been discussing a potential list of products for
local public procurement only. Kenya has a draft Trade Facilitation
Act that would allow complaints by local firms alleging dumping by
external suppliers.
Protecting margins on basic essentials can also provide ‘infant in-
dustry’ protection for upgrading, by giving local firms competitive
breathing space to improve capabilities (Sutton 2012; West and
Banda 2016). All local manufacturers interviewed were struggling to
upgrade their plant, and manufacturing and quality assurance (QA)
processes, to GMP standards; to expand their technical capabilities
and product range; and to meet rising regulatory standards.
Technical support such as that provided by German and Japanese
assistance can help to exploit industrial protection to achieve rising
quality. Grants, investments, and technology transfer can generate
step-improvements in technological capabilities and process and
product management, and reduce costs. Investments by public/pri-
vate global partnerships such as Drugs for Neglected Diseases are
creating one-off upgrades in locally based firms. A new start-up in
Tanzania is working with German equipment suppliers to ensure
high standards.
The Tanzanian government is increasingly providing land, infra-
structural support and access to local longer-term loan capital, as
Table 3. Amoxicillin tablets/capsules of Tanzanian manufacturing
origin, by sector of facility or shop (percentage of all amoxicillin
found on shelves on day of visit)
Year Public FBO/NGO Private Total
2006 93 77 67 79
2009 100 81 48 74
2012 0 13 25 14
2013a 0 0 0 0
Sources: 2006; 2009; 2012: WHO/HAI primary survey data used by per-
mission of Mary Justin-Temu.
a2013 authors’ primary data, not a comparable sample.
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support for new ventures. Incentivizing new investment increases
domestic competition and can exert downward pressure on prices.
Policy should incentivize firms’ learning to use and adapt imported
technology, through effective technology transfer (Kumar et al.
1999) and extracting benefits from industrial clustering. Successful
clusters encourage collaboration as well as competition, supporting
shared technological knowledge and learning between firms
(Malmberg and Maskell 2002; Ernst and Lundvall 1997).
Global Fund procurement now recognizes that to improve, learn,
invest and reduce costs, local firms must sell, and it aims to reduce
barriers to global market entry by competent firms in Africa. Local
firms face a disincentive to apply for expensive WHO pre-
qualification because they are unlikely to win tenders against Indian
competition. Therefore, for prequalified firms, the Global Fund now
uses a broader definition of value, called ‘total landed cost’, includ-
ing points for shorter lead times and responsiveness achieved
through market proximity (local firms’ most important competitive
advantage). Tender success by African suppliers is increasing,
including long-lasting insecticide-treated bed nets from A to Z in
Arusha, a firm with in-house regional logistics, and ACTs from
Cipla Quality Chemicals in Kampala. Global Fund tenders further-
more are not ‘winner takes all’: the aim is a range of competitive
suppliers, and prices vary within one tender: the tender outcome sets
a ‘reference price’ for an item; a single price is then paid by each
country. The Global Fund’s guiding principles of value for money,
quality (WHO-prequalification) and sustainability (affordability)
exclude subsidies to firms; however, this procurement strategy
strengthens incentives to reach international standards: ‘the carrot
at the end of the [local firms’] journey’. For health systems, the jour-
ney is towards an efficient, diverse and competitive local supplier
base, improving and sustainable over time.
Incentives to meet shared local needs: regulation and training
Policies to incentivize regulation and higher levels of pharmaceutical
skills were identified as core shared health and industrial needs.
Strong regulation incentivizes and supports manufacturers to reach
GMP standards required for entry to donor-funded markets. Rising
standards also generate merited trust in local products by clinicians
and patients. Effective regulation is a shared enterprise: a complex
mix of standard setting, inspection, enforcement, advice and sup-
port, checking of procured supplies, post-market vigilance and
following-up users’ complaints. Manufacturers and health system
actors interviewed in both research rounds agreed that external sup-
port for regulatory improvement at national and East African re-
gional level had reduced sub-standard and counterfeit medicines in
the private market, and improved quality.
The region, however, lacks key regulatory infrastructure such as
high-quality reference laboratories, and needs a stronger scientific
and technical base to support regulatory and training institutions.
Regulatory effectiveness is uneven, with Tanzania generally recog-
nized as having the strongest regulator, while Kenyan health sector
and manufacturing interviewees were looking for regulatory im-
provement. Strengthening regulation incentivizes joint venture de-
velopment and technology transfer: an interviewee from a
multinational firm in 2017 stated that they were ‘aware of some of
the key weaknesses of local pharma [in Kenya], for example around
quality assurance and quality inspection procedures, and would not
want to put our reputation at risk’. Regional regulatory harmoniza-
tion is advocated by manufacturers to simplify intra-regional ex-
ports, and NEPAD’s Africa Medicines Regulatory Harmonisation
(AMRH) provides a platform, as would the mooted Africa
Medicines Agency. Local regulators can exercise closer oversight of
local as compared to Indian firms, but regulatory ‘capture’ remains
a danger. Supporting effective independent regulators is a key role
for external actors.
Skills and training was seen by many as the area most in need of
investment. Health systems need more effective supply chain and
procurement management, but lack the necessary trained staff
(Waako et al. 2009; Wiedenmayer et al. 2015; Yadav 2015). In
2013, 53% of Kenyan and 73% of Tanzanian health facility inter-
viewees responsible for ordering had no relevant training. They also
lack competent laboratory technicians. Nationally, medicines policy
and health management need clinical pharmacists and pharmaco-
logical scientists.
These requirements overlap with the needs of industry.
Pharmaceutical technicians represent one large cross-sector gap.
Industrial laboratories struggle to recruit and retain skilled staff. All
manufacturers cited industrial pharmacy and chemical engineering
skills needs as well as biochemistry, microbiology, biomedical engin-
eering and other allied sciences. Across the region, some tertiary in-
stitutions are introducing industry attachments, but much more is
needed as the technical and scientific base for industrial growth
(MIT and UNIDO 2012). Industrial development creates incentives
for mutually beneficial pharmaceutical training.
Medicines policy and regulation, several stakeholders argued,
must bridge the health–industry divide. A professional association
official argued for the need to ‘cook our own food’ through profes-
sionalism and good regulation. Regulation of a knowledge industry
such as pharmaceuticals is underpinned by science, technology and
innovation; medicines policy is underpinned by clinical skills; and
the two must work together locally. Skills inadequacies not only im-
pede these ends, but, as one Kenyan respondent noted, they ‘also
leave the few and over-stretched professionals available vulnerable
to manipulation through corrupt practices’. The Science Technology
and Innovation Strategy for Africa (STISA 2024) (African Union
2014b) speaks to this need to build regulatory and laboratory qual-
ity assurance skills through initiatives such as U.S. Pharmacopeial
Convention (USP) Ghana’s Centre for Pharmaceutical Advancement
and Training (CePAT). In Southern Africa, regulation and skills
training are being collaboratively developed through the
ZAZIBONA (Zambia, Zimbabwe, Botswana and Namibia) initia-
tive, matching experienced with inexperienced regulators in joint in-
spections across the four countries, to feed into NEPAD’s AMRH
programme.
Discussion: ‘local health’ and ‘global health’:
questions of framing
Embedding local health system strengthening in local industrial de-
velopment challenges silos of thought in global health. Rooted in
earlier international health work that extended public health con-
cerns across geographical boundaries (Battams and Matlin 2013),
the global health literature and campaigning has generated initia-
tives by ‘global’—i.e., high income country-based—actors to address
vast international disparities in mortality, morbidity and human
wellbeing (Koplan et al. 2009; Rowson et al. 2012). These initia-
tives, by The Global Fund, the US President’s Emergency Plan for
AIDS Relief (PEPFAR) and others, have saved huge numbers of lives
and also, importantly, have reframed understanding and obligation
within high-income countries.
Nevertheless, the global health field is framed and dominated
by commentators, researchers, funders and campaigners based in
high income countries, with associated positions of power and
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privilege (Horton 2014; Shiffman et al. 2016; Sheikh et al. 2017).
The positionality of the global health field is reflected in its theme
of globalization, of porous borders and global threats (Macfarlane
et al. 2008). It converges with a growing literature on health secur-
ity addressing cross-border fast-moving infectious diseases, HIV
and biological weapons/bioterrorism, focusing public and policy at-
tention on protecting high income populations from diseases ema-
nating from low- and middle-income countries (Aldis 2008;
Rushton 2011; Flahault et al. 2016). Global health actors, further-
more, have operated on the underlying assumption that medical
health technologies are readily available commodities; that utiliza-
tion and access can be generated in a timely manner from global
pharmaceutical value chains; and that ‘global’ advances in know-
ledge benefit all.
For ‘local health’ actors, none of these assumptions look secure:
the risk calculation is different. Diversification of supply to include
competent Africa-based firms promises to reduce risk in the medium
term, as do increasingly responsive local supply chains. A Kenyan
interviewee argued in 2017 that emergency preparedness is a whole
system challenge, including responsive suppliers and the industrial
and scientific capabilities to address future challenges. Proximity
and health–industrial linkages then move from irrelevance to cen-
trality in local policy concerns.
Positionality outside high income contexts thus generates dis-
tinctive health needs and priorities, time-scales and perceptions of
opportunities and risks (and risk management) in crafting robust
health systems in Africa through building local capabilities. The
WHO’s ‘building blocks’ for health system strengthening include ac-
cess to essential medicines (WHO 2010); they do not include the in-
dustrial capabilities to supply those commodities. African policy
makers are shifting however from perceiving industrial and health
sector development as in competition, to perceiving symbiosis: a
good example is the Tanzanian government’s recent sharp increase
in budgeted tax funding for public medicines procurement, recogniz-
ing the mutual health and industrial benefits. The increasingly influ-
ential African ‘local health’ perspective outlined in this article
implies a paradigm shift to embed health system strengthening
within polices and narratives for inclusive and sustainable industrial
development.
Conclusion
While the African ‘local health’ perspective is distinct from global
health viewpoints, it is not necessarily in contradiction, as the shift-
ing Global Fund procurement processes illustrate. A local health
framework, focused on exploiting the interrelated health and indus-
trial benefits from proximity, throws into relief the relevance of
positionality. It challenges global health actors to recognize and
manage their own (large) industrial impact, and to do so in recog-
nition of the legitimate agency of African policy makers in seeking
medium term strengthening of their local health–industrial
linkages and associated scientific and industrial capabilities in the
interests of sustainably stronger local health systems and a stronger
industrial base. From African perspectives, the huge rise in medi-
cines procurement for SSA, arising from global health initiatives,
has opened opportunities to link industrial development into
strengthening their own health systems in the medium term.
This article has sought to outline a ‘local health’ perspective, based
in East African evidence, on some of the key opportunities to align
industrial and health objectives to the cumulative benefit of both
sectors.
Notes
1. Funded by DFID/ESRC, see Funding statement.
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3. Global Fund information from interviews, cited with
permission.
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